Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.80 |
| ▸ | F2 | P00734 | 1/20 | 0.80 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78030 | 1.00 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15846698 | 0.91 | F10 (0.83) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15326026 | 0.90 | F10 (0.81) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL78508 | 0.89 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Rivaroxaban SCHEMBL3914 | 0.89 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Rivaroxaban SCHEMBL77766 | 0.89 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Rivaroxaban SCHEMBL7721848 | 0.89 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Rivaroxaban SCHEMBL14796329 | 0.88 | F10 (0.98) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL78728 | 0.87 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL87235 | 0.87 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099453-B1 | Combination therapy of substituted oxazolidinones | BAYER IP GMBH (DE) | 2017-09-06 | — | — | EP | disclosed |
| US-7576111-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AG (DE) | 2009-08-18 | — | — | US | disclosed |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | BAYER HEALTHCARE AG | 2008-12-11 | — | — | US | disclosed |
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090815-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885CYP1A2 46/4885CYP3A4 42/4885 |
| US-20080306070-A1 | Combination Therapy Comprising Substituted Oxazolidinones for the Prevention and Treatment of Cerebral Circulatory Disorders | OTC, SDHA, SDHB | F10 258/4885CYP1A2 123/4885CYP3A4 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.